1. 24TiPKEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer. (24th November 2019) Authors: Cardoso, F; Bardia, A; André, F; Cescon, D W; McArthur, H; Telli, M; Loi, S; Cortes, J; Schmid, P; Harbeck, N; Denkert, C; Jackisch, C; Jia, L; Hirshfield, K; Karantza, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗